Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

doi:10.1007/s11684-014-0319-1

Front. Med.

2014, Vol. 8

Issue (2) : 254-258 https://doi.org/10.1007/s11684-014-0319-1

CASE REPORT

Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock

Muhammad Furqan¹,Yamei Chen^1,²,Akintunde Akinleye¹,Judy Sarungbam³,Alan Gass⁴,Karen Seiter¹,Delong Liu^1,^*(

)

1. Division of Hematology and Oncology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA
2. Department of Hematology, Xiamen Zhongshan Hospital, Xiamen University, Xiamen 361004, China
3. Department of Pathology, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA
4. Division of Cardiology, Department of Medicine, Westchester Medical Center, 100 Woods Rd, Valhalla, NY 10595, USA

Download: PDF(922 KB) HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Mantle cell lymphoma is an aggressive subtype of B cell non-Hodgkin lymphoma. It can progress to leukemic phase but frank leukemic picture at initial presentation is not common. Leukemic phase indicates advance stage of the disease and generally associated with extensive extra-nodal involvement. Pericardial invasion has been reported, however we could not find a report of myocardial infiltration by this disease since the appraisal of the term “mantle cell lymphoma” in 1992. Here we report a case of cardiac involvement by mantle cell leukemia leading to cardiogenic shock which complicates the treatment decisions.

Keywords mantle cell lymphoma bendamustine cardiogenic shock

Corresponding Author(s): Delong Liu

Issue Date: 21 May 2014

Cite this article:

Muhammad Furqan,Yamei Chen,Akintunde Akinleye, et al. Management of mantle cell leukemia with cardiac involvement leading to cardiogenic shock[J]. Front. Med., 2014, 8(2): 254-258.

URL:

https://academic.hep.com.cn/fmd/EN/10.1007/s11684-014-0319-1
https://academic.hep.com.cn/fmd/EN/Y2014/V8/I2/254

Fig.1 Mantle cell lymphoma involving myocardium. (A) Peripheral blood smear showing several medium-sized lymphocytes with cleaved nuclei. (B–D, H and E) stained myocardial tissue shown at different magnifications to demonstrate disintegrated cardiac muscle fibers with sheets of mononuclear infiltrate. (E–F) Cyclin D1 and CD5 immunohistochemical staining of endomyocardial biopsy tissue depicting positivity of cyclin D1 and CD5 by mononuclear cells infiltrating the myocardium.

1	BanksPM, ChanJ, ClearyML, DelsolG, Wolf-PeetersCD, GatterK, GroganTM, HarrisNL, IsaacsonPG, JaffeES, MasonD, PileriS, RalfikiaerE, SteinH, WarnkeRA. Mantle cell lymphoma.A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol1992; 16(7): 637-640 doi: 10.1097/00000478-199207000-00001 pmid: 1530105
2	ShivdasaniRA, HessJL, SkarinAT, PinkusGS. Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin's lymphoma. J Clin Oncol1993; 11(4): 802-1118478674
3	CampoE, RaffeldM, JaffeES. Mantle-cell lymphoma. Semin Hematol1999; 36(2): 115-127 pmid: 10319380
4	ArmitageJ. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma.The Non-Hodgkin’s Lymphoma Classification Project. Blood1997; 89(11): 3909-3918 pmid: 9166827
5	PittalugaS, BijnensL, TeodorovicI, HagenbeekA, MeerwaldtJH, SomersR, ThomasJ, NoordijkEM, De Wolf-PeetersC. Clinical analysis of 670 cases in two trials of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group subtyped according to the Revised European-American Classification of Lymphoid Neoplasms: a comparison with the Working Formulation. Blood1996; 87(10): 4358-4367 pmid: 8639796
6	KauhJ, BaidasSM, OzdemirliM, ChesonBD. Mantle cell lymphoma: clinicopathologic features and treatments. Oncology (Williston Park, NY)2003; 17(6): 879-891, 896; discussion 896-878
7	BigoniR, NegriniM, VeroneseML, CuneoA, CastoldiGL, CroceCM. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene1996; 13(4): 797-802 pmid: 8761301
8	ArgatoffLH, ConnorsJM, KlasaRJ, HorsmanDE, GascoyneRD. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood1997; 89(6): 2067-2078 pmid: 9058729
9	SamahaH, DumontetC, KettererN, MoulletI, ThieblemontC, BouafiaF, Callet-BauchuE, FelmanP, BergerF, SallesG, CoiffierB. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia1998; 12(8): 1281-1287 doi: 10.1038/sj.leu.2401121 pmid: 9697885
10	Parry-JonesN, MatutesE, MorillaR, Brito-BabapulleV, WotherspoonA, SwansburyGJ, CatovskyD. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol2007; 137(2): 117-124 doi: 10.1111/j.1365-2141.2007.06526.x pmid: 17391491
11	FerryJA. Extranodal lymphoma. Arch Pathol Lab Med2008; 132(4): 565-578 pmid: 18384208
12	AmbinderAJ, ShenoyPJ, NastoupilLJ, FlowersCR. Using primary site as a predictor of survival in mantle cell lymphoma. Cancer2013; 119(8): 1570-1577 doi: 10.1002/cncr.27898 pmid: 23341329
13	BertiniM, RusC, FreiloneR, BottoB, CalviR, NoveroD, OrsucciL, VitoloU, PalestroG, ResegottiL. Mantle cell lymphoma: a retrospective study on 27 patients.Clinical features and natural history. Haematologica1998; 83(4): 312-316 pmid: 9592980
14	BernardM, GressinR, LefrèreF, DrénouB, BrangerB, Caulet-MaugendreS, TassP, BrousseN, ValensiF, MilpiedN, VoilatL, SadounA, GhandourC, HunaultM, LeloupR, MannoneL, HermineO, LamyT. Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype. Leukemia2001; 15(11): 1785-1791 doi: 10.1038/sj.leu.2402272 pmid: 11681422
15	FerrerA, BoschF, VillamorN, RozmanM, GrausF, GutiérrezG, MercadalS, CampoE, RozmanC, López-GuillermoA, MontserratE. Central nervous system involvement in mantle cell lymphoma. Ann Oncol2008; 19(1): 135-141 doi: 10.1093/annonc/mdm447 pmid: 17962207
16	EveHE, FurtadoMV, HamonMD, RuleSA. Time to treatment does not influence overall survival in newly diagnosed mantle-cell lymphoma. J Clin Oncol2009; 27(32): e189-e190, author reply e191 doi: 10.1200/JCO.2009.23.9731 pmid: 19805667
17	MartinP, ChadburnA, ChristosP, WeilK, FurmanRR, RuanJ, ElstromR, NiesvizkyR, ElyS, DilibertoM, MelnickA, KnowlesDM, Chen-KiangS, ColemanM, LeonardJP. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol2009; 27(8): 1209-1213 doi: 10.1200/JCO.2008.19.6121 pmid: 19188674
18	GhielminiM, RufibachK, SallesG, Leoncini-FransciniL, Léger-FalandryC, CogliattiS, FeyM, MartinelliG, StahelR, LohriA, KettererN, WernliM, CernyT, SchmitzSF. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol2005; 16(10): 1675-1682 doi: 10.1093/annonc/mdi320 pmid: 16030029
19	GhielminiM, SchmitzSFH, CogliattiS, BertoniF, WaltzerU, FeyMF, BetticherDC, ScheferH, PichertG, StahelR, KettererN, BargetziM, CernyT; Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol2005; 23(4): 705-711 doi: 10.1200/JCO.2005.04.164 pmid: 15598978
20	SchulzH, BohliusJF, TrelleS, SkoetzN, ReiserM, KoberT, SchwarzerG, HeroldM, DreylingM, HallekM, EngertA. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst2007; 99(9): 706-714 doi: 10.1093/jnci/djk152 pmid: 17470738
21	CangS, MukhiN, WangK, LiuD. Novel CD20 monoclonal antibodies for lymphoma therapy. J Hematol Oncol2012; 5(1): 64 doi: 10.1186/1756-8722-5-64 pmid: 23057966
22	WangK, WeiG, LiuD. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol2012; 1(1): 36 doi: 10.1186/2162-3619-1-36 pmid: 23210908
23	CoiffierB. Rituximab in combination with CHOP improves survival in elderly patients with aggressive non-Hodgkin’s lymphoma. Semin Oncol2002; 29(2 Suppl 6): 18-22 doi: 10.1053/sonc.2002.32749 pmid: 12040530
24	ZhaoJ, XuZ, LiuD, LuQ. Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting. Cancer Cell Int2012; 12(1): 38 doi: 10.1186/1475-2867-12-38 pmid: 22913602
25	GhielminiM, ZuccaE. How I treat mantle cell lymphoma. Blood2009; 114(8): 1469-1476 doi: 10.1182/blood-2009-02-179739 pmid: 19556426
26	RummelMJ, NiederleN, MaschmeyerG, BanatGA, von GrünhagenU, LosemC, Kofahl-KrauseD, HeilG, WelslauM, BalserC, KaiserU, WeidmannE, DürkH, BalloH, StauchM, RollerF, BarthJ, HoelzerD, HinkeA, BruggerW; Study group indolent Lymphomas (StiL).Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet2013; 381(9873): 1203-1210 doi: 10.1016/S0140-6736(12)61763-2 pmid: 23433739
27	JacobsonCA, FreedmanAS. First-line treatment of indolent lymphoma: axing CHOP? Lancet2013; 381(9873): 1163-1165 doi: 10.1016/S0140-6736(12)61965-5 pmid: 23433738
28	LuK, WangX. Therapeutic advancement of chronic lymphocytic leukemia. J Hematol Oncol2012; 5(1): 55 doi: 10.1186/1756-8722-5-55 pmid: 22980425
29	AkinleyeA, FurqanM, MukhiN, RavellaP, LiuD. MEK and the inhibitors: from bench to bedside. J Hematol Oncol2013; 6:27 doi: 10.1186/1756-8722-6-27 pmid: 23587417
30	WuM, AkinleyeA, ZhuX. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol2013;6:36 doi: 10.1186/1756-8722-6-36 pmid: 23680477
31	ZhaoY, HuangH, WeiG. Novel agents and biomarkers for acute lymphoid leukemia. J Hematol Oncol2013;6:40 doi: 10.1186/1756-8722-6-40 pmid: 23773228
32	WangML, RuleS, MartinP, GoyA, AuerR, KahlBS, JurczakW, AdvaniRH, RomagueraJE, WilliamsME, BarrientosJC, ChmielowskaE, RadfordJ, StilgenbauerS, DreylingM, JedrzejczakWW, JohnsonP, SpurgeonSE, LiL, ZhangL, NewberryK, OuZ, ChengN, FangB, McGreivyJ, ClowF, BuggyJJ, ChangBY, BeaupreDM, KunkelLA, BlumKA. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med2013; 369(6): 507-516 doi: 10.1056/NEJMoa1306220 pmid: 23782157
33	ByrdJC, FurmanRR, CoutreSE, FlinnIW, BurgerJA, BlumKA, GrantB, SharmanJP, ColemanM, WierdaWG, JonesJA, ZhaoW, HeeremaNA, JohnsonAJ, SukbuntherngJ, ChangBY, ClowF, HedrickE, BuggyJJ, JamesDF, O’BrienS. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med2013; 369(1): 32-42 doi: 10.1056/NEJMoa1215637 pmid: 23782158
34	AkinleyeA, ChenY, MukhiN, SongY, LiuD. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol2013; 6:59 doi: 10.1186/1756-8722-6-59 pmid: 23958373

[1]

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang. Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma[J]. Front. Med., 2020, 14(6): 811-815.

Viewed

Full text

Abstract

Cited

Shared

Discussed